Purpose To determine the maximum tolerated dose of radiation therapy (RT) given in an
accelerated fashion with concurrent chemotherapy using intensity modulated RT. Methods …

We report a phase II study to evaluate the survival rate, response rate and toxicity of
concurrent chemoradiation therapy (CCRT) followed by consolidation chemotherapy (CT) …

The purpose of this pilot study was to determine the safety and feasibility of accelerated
fractionation (via concomitant boost) radiotherapy (XRT) with concurrent …

Background Cisplatin-based chemotherapy administered concurrently to thoracic radiation
therapy is the recommended treatment for fit patients with unresectable stage III NSCLC. The …

Concurrent chemoradiotherapy (CHRT) is the standard of care for unresectable locally
advanced stage III non-small cell lung cancer. However, the optimal combination remains …

Currently, combinations of chemotherapy and radiotherapy are the standard treatment
approach for locally advanced NSCLC patients. Concomitant chemo-radiotherapy, although …

The optimal strategy for the non-surgical definitive treatment of patients with good
performance status non-small cell lung cancer (mostly with locally advanced disease) has …

Opinion statement The incidence of cancer among older patients continues to rise. The use
of combined modality therapy has improved survival in a variety of malignancies, including …

Locally advanced disease non–small cell lung cancer (NSCLC) usually refers to stage III
disease. After a recent move of T3 N0 to stage IIB, stage III still has a number of possible T …

Lung cancer remains the leading cause of cancer death in the United States. The standard
of care for patients with locally advanced non–small-cell lung cancer is radiation plus …